• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.

作者信息

Vigne Jonathan, Chrétien Basile, Bignon Anne-Laure, Bouhier-Leporrier Karine, Dolladille Charles

机构信息

Department of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, Avenue de La Côte de Nacre, CS 30001, 14033 Caen CEDEX 9, Caen, France.

Department of Pharmacy, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000, Caen, France.

出版信息

Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3332-3333. doi: 10.1007/s00259-022-05833-6. Epub 2022 May 6.

DOI:10.1007/s00259-022-05833-6
PMID:35513605
Abstract
摘要

相似文献

1
[Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.[陆] 镥-奥曲肽肽受体放射性核素治疗相关的髓系肿瘤：来自世界卫生组织药物警戒数据库的见解
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3332-3333. doi: 10.1007/s00259-022-05833-6. Epub 2022 May 6.
2
Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.[ 177 Lu]Lu-HA-DOTATATE 治疗后的外渗。
Clin Nucl Med. 2024 May 1;49(5):454-456. doi: 10.1097/RLU.0000000000005137. Epub 2024 Mar 6.
3
Lu-DOTATATE Peptide Receptor Radionuclide Therapy.镥-奥曲肽肽受体放射性核素治疗
J Nucl Med Technol. 2022 Sep;50(3):203-204.
4
Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177 Lu-DOTATATE.仅经过 2 个周期的 177Lu-DOTATATE 治疗，快速生长的胰腺神经内分泌癌转移性淋巴结聚集体的体积显著缩小。
Clin Nucl Med. 2022 Nov 1;47(11):961-962. doi: 10.1097/RLU.0000000000004262. Epub 2022 Jun 11.
5
Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.镥-177 和钇-90 肽受体放射性核素治疗神经内分泌肿瘤患者的肝并发症。
Nucl Med Rev Cent East Eur. 2022;25(1):54-61. doi: 10.5603/NMR.a2022.0016.
6
An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (Lu)-DOTATATE.神经内分泌肿瘤患者接受镥 177（Lu）-DOTATATE 治疗的治疗剂量分析。
Cancer Biother Radiopharm. 2022 Feb;37(1):17-22. doi: 10.1089/cbr.2021.0071. Epub 2021 Jun 16.
7
Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.一名患有转移性胃肠道神经内分泌肿瘤和脑膜瘤的患者接受¹⁷⁷Lu-DOTATATE肽受体放射性核素治疗的管理
Clin Nucl Med. 2022 Nov 1;47(11):e692-e695. doi: 10.1097/RLU.0000000000004307. Epub 2022 Jun 11.
8
Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Y/Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study.Y/Lu-DOTATATE串联肽受体放射性核素治疗神经内分泌肿瘤的长期疗效及耐受性与原发部位的关系：一项10年研究
Ann Nucl Med. 2017 Jun;31(5):347-356. doi: 10.1007/s12149-017-1163-6. Epub 2017 Mar 18.
9
Efficacy and Safety of Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.Lu-DOTATATE 在肺部神经内分泌肿瘤中的疗效和安全性：一项多中心研究。
J Nucl Med. 2022 Feb;63(2):218-225. doi: 10.2967/jnumed.120.260760. Epub 2021 May 28.
10
Lu-DOTATATE treatment in neuroendocrine tumours. A preliminary study.177Lu-DOTATATE治疗神经内分泌肿瘤：一项初步研究
Rev Esp Med Nucl Imagen Mol. 2017 Mar-Apr;36(2):91-98. doi: 10.1016/j.remn.2016.10.003. Epub 2016 Nov 23.

引用本文的文献

1
Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors.肠胰神经内分泌肿瘤肽受体放射性配体治疗后持续性血小板减少症的预测因素
Front Endocrinol (Lausanne). 2025 May 15;16:1568243. doi: 10.3389/fendo.2025.1568243. eCollection 2025.
2
Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT.筛查克隆性造血以降低肽受体放射性核素治疗后造血肿瘤的风险。
World J Nucl Med. 2023 Apr 28;22(2):150-151. doi: 10.1055/s-0043-1764308. eCollection 2023 Jun.
3
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.

本文引用的文献

1
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lu-Dotatate 联合长效奥曲肽与高剂量长效奥曲肽治疗肠神经内分泌肿瘤患者（NETTER-1）：一项开放标签、随机、对照、III 期临床试验的最终总生存和长期安全性结果。
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
2
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.肽受体放射性核素/化学放射性核素治疗（PRRT/PRCRT）治疗转移性神经内分泌肿瘤后治疗相关髓系肿瘤的特征和结局：单机构系列研究。
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11.
3
基于镥-177的放射性药物的安全性与治疗优化
Pharmaceutics. 2023 Apr 13;15(4):1240. doi: 10.3390/pharmaceutics15041240.
Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.[Lu-DOTA,Tyr]奥曲肽挽救性肽受体放射性核素治疗支气管和胃肠胰腺神经内分泌肿瘤。
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28.
4
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.